What is the Market's View on Exelixis, Inc. (EXEL) Stock's Price and Volume Trends Monday?

Overall market sentiment has been high on Exelixis, Inc. (EXEL) stock lately. EXEL receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Exelixis, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on EXEL!

See Full EXEL Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With EXEL Stock Today?

Exelixis, Inc. (EXEL) stock is higher by 0.71% while the S&P 500 is down -1.52% as of 10:31 AM on Monday, Dec 20. EXEL is higher by $0.13 from the previous closing price of $18.20 on volume of 312,027 shares. Over the past year the S&P 500 is higher by 23.15% while EXEL is down -8.67%. EXEL earned $0.51 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 35.67. To see InvestorsObserver's Sentiment Score for Exelixis, Inc. click here.

More About Exelixis, Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma. Click Here to get the full Stock Report for Exelixis, Inc. stock.